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Abstract: Subcellular compartmentation is a fundamental property of eukaryotic cells. Commu-
nication and metabolic and regulatory interconnectivity between organelles require that solutes
can be transported across their surrounding membranes. Indeed, in mammals, there are hundreds
of genes encoding solute carriers (SLCs) which mediate the selective transport of molecules such
as nucleotides, amino acids, and sugars across biological membranes. Research over many years
has identified the localization and preferred substrates of a large variety of SLCs. Of particular
interest has been the SLC25 family, which includes carriers embedded in the inner membrane of
mitochondria to secure the supply of these organelles with major metabolic intermediates and coen-
zymes. The substrate specificity of many of these carriers has been established in the past. However,
the route by which animal mitochondria are supplied with NAD+ had long remained obscure.
Only just recently, the existence of a human mitochondrial NAD+ carrier was firmly established.
With the realization that SLC25A51 (or MCART1) represents the major mitochondrial NAD+ carrier
in mammals, a long-standing mystery in NAD+ biology has been resolved. Here, we summarize the
functional importance and structural features of this carrier as well as the key observations leading
to its discovery.
Keywords: mitochondrial carrier; mitochondrial transporter; membrane transport; mitochondria;
solute carrier family 25; SLC25; SLC25A51; NAD+ transporters; NAD
1. Introduction
Transmembrane transport proteins (transporters or carriers) catalyse the translocation
of specific ions, nutrients, metabolites, cofactors, and proteins across biological membranes,
which otherwise would be impermeable to these molecules. It has been estimated that 10%
of all human genes encode polypeptides involved in solute transport across the plasma
and intracellular membranes [1]. Based on sequence homology, more than 400 human
transporters have been classified into 66 solute carrier (SLC) protein families, excluding
active transporters (ABC transporters and ATPase pumps) and ion channels [1,2]. For ex-
ample, members of the major facilitator superfamily, which have twelve transmembrane
helices, are subdivided into various SLC families, and mitochondrial carriers, which have
six transmembrane helices, belong to the SLC25 family. About 30% of the SLCs are orphans,
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i.e., what they transport is unknown. There is also a long list of molecules that are probable
substrates of yet unidentified transporters based on the knowledge about the cellular
compartmentalization of enzymes and biochemical compounds. It is a great challenge
to find the missing pieces in this metabolic puzzle, trying to identify the physiological
substrate for a transporter or vice versa.
Nicotinamide adenine dinucleotide (NAD+) is the most widely used cofactor of enzy-
matic redox reactions in the cell. It has the capacity to be an electron donor in its reduced
form (NADH) and electron acceptor in its oxidized form (NAD+). It is also an important
signalling molecule involved in a multitude of signalling processes in different cellular
compartments. NAD+ appears to be present in all cellular organelles, with mitochondria
containing up to 70% of the total cellular NAD+ [3]. There are several routes of NAD+
biosynthesis. With regard to the pyridine base, NAD+ can be synthesized from several
different precursors in animals: nicotinamide (Nam) and nicotinic acid (together known
as vitamin B3), tryptophan, and nicotinamide riboside (NR). They are obtained from diet
and imported into cells by various SLC transporters (SLC5A8, SLC22A13, and members
of the SLC29 family for vitamin B3; e.g., SLC7A5 and SLC36A4 for tryptophan) [4,5].
The majority of NAD+ is synthesized from nicotinamide, which is also released by NAD+
consuming signalling reactions (Figure 1). The first enzyme of the so-called NAD+ sal-
vage pathway is nicotinamide phosphoribosyl transferase (NAMPT) and is predominantly
localized to the cytosol and the nucleus [6,7]. To maintain mitochondrial NAD+ concentra-
tions, cytoplasmic NAD+ or an NAD+ intermediate, such as nicotinamide mononucleotide
(NMN), need to be imported into mitochondria. It has been known for a long time that
NADH cannot be transported directly into mitochondria. Various systems have evolved to
shuttle the reducing equivalents of cytosolic NADH into the mitochondrial matrix, e.g.,
the malate-aspartate and glycerol-3-phosphate shuttles [8,9]. Proteins, which all belong to
the mitochondrial carrier family, have been identified that transport NAD+, and to a lesser
extent, NMN and nicotinic acid adenine dinucleotide (NAAD), in yeast and plant mito-
chondria [10,11] or NAD+ into human and plant peroxisomes [12–14]. However, until very
recently, no NAD+ transporter had been found in animal mitochondria.
In 2020, SLC25A51 (along with SLC25A52, which is 96% identical) was concluded to
be a human mitochondrial NAD+ transporter by three independent research teams [15–17].
Although SLC25A51 is a member of the mitochondrial carrier family, it is not a close
homologue of previously identified NAD+ carriers. Using functional assays, yeast comple-
mentation, and genetic engineering, the role of SCL25A51 as a human mitochondrial NAD+
transporter was established. These approaches are different from the EPRA method (where
the protein is recombinantly expressed, purified, and reconstituted into liposomes for
transport assays in vitro) that has been applied for the identification of the NAD+ carriers
in plants and yeast and the majority of the other SLC25 members. The SLC25 carrier family
transports a wide range of substrates from protons, inorganic ions, and small metabolites
to nucleotides and large cofactors [18]. In this review, human NAD+ metabolism and its
compartmentalisation as well as the discovery and characteristics of SLC25A51 and the
other NAD+ carriers are discussed.
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Figure 1. Compartmentalisation of NAD+ biosynthesis and salvage pathway in human cells. The fig-
ure shows the compartmentalisation of NAD+ synthesis, consumption, and salvage. The three
different isoforms of NMNAT show distinct subcellular localisations with NMNAT1 primarily local-
ized to the nucleus, NMNAT2 localized to the Golgi apparatus, and NMNAT3 in the mitochondria.
The peroxisomal and mitochondrial SLC transporters are highlighted in green. (Abbrev.: Nam: nicoti-
namide; NMN: nicotinamide mononucleotide; NMNAT1/2/3: NMN adenylyltransferase 1/2/3;
SIRT: sirtuin; PARP: poly-ADP-ribosyl polymerase; NAMPT: Nam phosphoribosyltransferase).
2. Human NAD+ Biosynthesis and Its Compartmentation
In human cells, the majority of NAD+ is produced from Nam in a two-step path-
way. The first step is catalysed by NAMPT in which NMN is formed from Nam and
phosphoribosylpyrophosphate (PRPP). The affinity of NAMPT towards its substrates is
enhanced by autophosphorylation of the enzyme, ATP being the phosphoryl donor [19].
Under these conditions, the affinity of NAMPT towards Nam is in the low nanomolar
range, thereby assuring efficient recycling of Nam produced from NAD+ in signalling
reactions (Figure 1) [20]. Formation of the dinucleotide, NAD+, is accomplished by NMN
adenylyltransferases, NMNATs. Mammalian cells have three NMNAT genes encoding
isoforms that are present in the nucleus (NMNAT1), the Golgi complex, facing the cytosol
(NMNAT2) and the mitochondria (NMNAT3) (Figure 1).
In addition to the NAMPT-dependent NAD+ synthesizing pathway, alternative pre-
cursors can also maintain cellular NAD+ homeostasis. Quinolinic acid, a product of
tryptophan degradation in the kynurenine pathway, is converted to NAMN, the acidic
form of NMN, and thereby enters NAD+ synthesis [21]. This route appears to be impor-
tant for liver NAD+ homeostasis, at least in mice [22]. Likewise, nicotinic acid is also
converted to NAMN by nicotinic acid phosphoribosyltransferase. NMNATs form the
dinucleotide, NAAD, from NAMN and ATP, in the same manner as NAD+ from NMN and
ATP [21]. Thus, all NAD+ biosynthetic pathways require NMNAT activity [23]. In mam-
mals, NAAD is amidated to NAD+ by NAD+ synthetase using glutamine as an amide
donor and the energy of ATP to accomplish the reaction [21]. Thereby, the conversion of
Nam to NAD+ through NAMPT activity is not only the shortest, but also the energetically
least-demanding pathway. This pathway is also known as Nam salvage pathway as it
is required to resynthesize NAD+ from Nam, generated by NAD-consuming signalling
reactions. NAD-dependent signalling reactions such as the de-acetylation of proteins by
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sirtuins or the mono- and poly-ADP-ribosylation through ADP-ribosyl transferases (ART)
or poly-ADP-ribosyltransferases (PARPs) [4,24,25], have been shown to lead to a constant
turnover of cellular NAD+ pools, resulting in half-lives of only a few hours in human
cells [22].
In recent years, the use of the nucleoside of Nam, NR, has gained tremendous interest.
Having the ribose already attached, it can be readily converted to NMN by phosphorylation,
thereby providing an efficient, PRPP-independent route to NAD+ [25,26]. Since NAMPT
represents the rate-limiting reaction in human NAD+ biosynthesis, bypassing it using NR
can potentially boost cellular NAD+ levels with a wide range of beneficial physiological ef-
fects. Likewise, dietary supplementation with NMN has also been proposed as a strategy to
improve NAD+ availability [25,27]. Physiological improvements have been largely ascribed
to the activation of NAD-dependent signalling pathways, in particular, SIRT-dependent
protein deacetylation. Furthermore, some beneficial effects of NAD+ supplementation have
been associated with enhanced mitochondrial functions, mediated, at least in part, by the
activation of nuclear SIRT1, resulting in transcriptional activation of genes promoting mito-
chondrial proliferation. However, there also appear to be direct mitochondrial effects that
might be explained by increased availability of NAD+ within these organelles. It should be
noted that, so far, effects of NR supplementation on mitochondrial function have largely
been observed in preclinical animal models, not humans.
NAD-dependent metabolic and signalling processes are strictly compartmentalized.
This raises the question how various NAD+ pools are formed and maintained, and how
they interact. To date, the cytosolic, nuclear, and mitochondrial NAD+ pools have been best
described. Using the PARAPLAY assay, which is based on expression of the catalytic do-
main of poly-ADP-ribosyltransferase 1 (PARP1) in various subcellular compartments [28],
pools of NAD+ in peroxisomes, ER, and Golgi complex [29,30] were demonstrated. It was
shown that NAD+ is transported into peroxisomes using the mitochondrial type carrier
SLC25A17 [13]. How NAD+ enters the ER or the Golgi complex is currently unknown.
For a long time, nuclear and cytosolic NAD+ were thought to form a single pool
as it was believed that the free dinucleotide can diffuse through nuclear pores whose
diameters are much larger than the size of NAD+. The analysis is complicated by the fact
that both NAMPT and NMNAT activities are present in both compartments and recent
work has demonstrated that the interactions between the nuclear and cytosolic NAD+
pools are complex. Using genetically encoded biosensors for NAD+ targeted to various
cellular compartments, it was suggested that the depletion of NMNAT2 in HEK293T cells
decreased cytoplasmic but not nuclear NAD+ concentrations [31]. Ryu et al. [32] found that
stimulation of NAD+ synthesis in the cytosol, through the induction of NMNAT2, leads to
a decrease in the level of NAD+ in the nucleus and suppression of PARP1 activity, regulating
the expression of genes involved in adipogenic differentiation. Moreover, a model was
proposed according to which the NAD+ nuclear pool is regulated by competition between
NMNAT1 and NMNAT2 for their common substrate, namely NMN. Thus, despite the
fact that we cannot exclude the direct exchange of NAD+ between the cytosol and the
nucleus, depletion of the dinucleotide in one compartment cannot be fully offset by another
pool. This may result in the nonviability of embryos observed in mice knocked out for
NMNAT1 [33] or NMNAT2 [34].
3. The Mitochondrial NAD+ Pool
Despite the important role of the mitochondrial NAD+ pool for cellular metabolism
and regulation, there are still many open questions related to its formation and mainte-
nance. As most available evidence suggests NMNAT3 to be a mitochondrial isoform [6,35],
it has been thought that NMNAT3 is essential to establish and maintain the mitochondrial
NAD+ pool. It has been shown that an increase in the level of cytosolic NMN leads to an
increase in the level of mitochondrial NAD+ in cultured human cells [6]. Based on these
data, it was suggested that the cytosolic precursor of mitochondrial NAD+ is the mononu-
cleotide NMN, which, after being imported into the mitochondrial matrix, is adenylated
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to the dinucleotide NAD+ by NMNAT3. This hypothesis was also supported by in vitro
data, according to which mitochondria isolated from rat liver can synthesize NAD+ from
NMN and ATP [36]. Using mitochondria isolated from murine skeletal muscle or C2C12
myoblasts, Davila et al. [37] confirmed this observation. However, they demonstrated that
the NMNAT activity was not located in the mitochondrial matrix but depended on the nu-
clear enzyme NMNAT1 [37]. Consequently, the detected mitochondria-associated NMNAT
activity may have been the result of a contamination with the nuclear protein. Increased
expression of NMNAT3 in transgenic mice and in cultured cells, however, efficiently in-
creases mitochondrial NAD+ levels in various tissues [38,39]. Suppressed expression of
this protein in some cells leads to a significant decrease in mitochondrial NAD+ concentra-
tions, while in others, it has no effect on the mitochondrial NAD+ pool [31]. Mice lacking
Nmnat3 have, nevertheless, normal mitochondrial dinucleotide levels in most tissues [40].
Moreover, NMNAT3 was found to play a key role in maintaining the NAD+ pool in mature
erythrocytes in which mitochondria are absent [41].
Thus, data on the role of NMNAT3 in maintaining the mitochondrial NAD+ pool have
remained controversial. NMNAT3 may be an important regulator of mitochondrial NAD+
content, but there need to be alternative mechanisms that mediate the generation of the
mitochondrial NAD+ pool.
In recent years, the focus of studies on the mechanisms of maintenance of mitochon-
drial NAD+ in mammals has shifted to reconsider the possibility of a transporter carrying
the dinucleotide into the organelles. It was found that NMNAT2 depletion in HEK293T
and HeLa cells decreased cytoplasmic and mitochondrial NAD+ levels, whereas NR did
not restore mitochondrial NAD+ concentrations in NMNAT2 knockdowns in HeLa cells.
These data suggested that NAD+ produced in the cytoplasm can influence mitochondrial
stores [31]. Moreover, using C2C12 cells and NAR labelled with two different isotopes
for ribose and Nam (13C on the pyridine carboxyl group and a deuterium on the ribose
moiety), Davila et al. [37] demonstrated the incorporation of both labels into mitochondrial
NAD+. Furthermore, given that NAR is converted to NAD+ in the cytosol via NAMN
and NAAD, the cytosolic NMN pool was not labelled. This led to the suggestion that
the mitochondrial NAD+ pool can be established through direct import of NAD+ [37].
These observations prompted intensive research efforts in various laboratories to address
the possibility of the existence of a mitochondrial NAD+ carrier in mammalian cells.
4. Identification of Mitochondrial NAD+ Transporters in Yeast, Plants, and Bacteria
The mitochondrial NAD+ carriers in Saccharomyces cerevisiae, Ndt1p, and Ndt2p,
which have 70% sequence identity, belong to the mitochondrial carrier family having
the typical signature motif sequences (conserved consensus sequences initiating with
PX[DE]XX[KR]) in three tandemly repeated domains [10]. These two proteins were ad-
dressed because they cluster with mitochondrial nucleotide carriers in phylogenetic trees
and especially close to the FAD transporter Flx1p and pyrimidine nucleotide transporter
Rim2p, which both have a rare tryptophan instead of the first negatively charged residue
of the second signature motif just like Ndt1p and Ndt2p [10]. The substrates of Ndt1p
were identified by the EPRA method, i.e., by expression in Escherichia coli, purification,
reconstituted into liposomes and transport assays [10,18,42]. Ndt1p, which was found to
be localized to mitochondria as well as Ndt2p, mainly transports NAD+ (Km of 0.38 mM),
and to a lesser extent, (d)AMP, (d)GMP, and NAAD. In addition, the nucleotides of uridine,
thymine, and cytosine were transported by Ndt1p less efficiently than those of adenine
and guanine with the following order of potency: monophosphates > diphosphates >
triphosphates. By contrast, α-NAD+, NADH, NMN, NAMN, as well as FAD and FMN
are very poor substrates of Ndt1p; and NADP, NADPH, Nam, and nicotinic acid are not
transported at all by Ndt1p [10]. Furthermore, this carrier functions as a slower uniporter
and a faster antiporter of substrates. In addition, yeast cells lacking Ndt1p or Ndt2p
have growth defects on non-fermentable carbon sources and reduced mitochondrial levels
of NAD+, a phenotype that becomes more pronounced in double knockout cells [10,43].
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It should be emphasized that in S. cerevisiae, there is good evidence that there are no NAD+
biosynthetic enzymes within mitochondria [10]. Based on the biochemical characterization
of Ndt1p, the high sequence identity between Ndt1p and Ndt2p, and the properties of the
deleted strains, it was concluded that the main physiological role of both Ndt1p and Ndt2p
is to import NAD+ from the cytosol into the mitochondrial matrix in exchange for (d)AMP
and (d)GMP [10].
Two of the 58 mitochondrial carriers of Arabidopsis thaliana, AtNDT1 and AtNDT2
(with 61% sequence identity in their carrier domains), display considerable similarity
to yeast Ndt1p and Ndt2p with percentages of identity ranging from 26 to 34% [11].
The transport properties of these two plant carriers were characterized by the EPRA method,
demonstrating that NAD+ is transported by both of them (Km values in submillimolar
range) as well as NAAD, NMN, ADP, and AMP, and to a lesser extent NAMN, FAD, FMN,
and several other nucleotides with the bases A, G, C, U, and T, whereas pyrophosphate
is only transported by AtNDT1 [11]. The specific activity of AtNDT2 is about three times
higher than that of AtNDT1 and both carriers exhibit antiport transport rates much higher
than those of uniport. Furthermore, the expression of AtNDT1 and AtNDT2 in yeast
lacking Ndt1p and Ndt2p restores mitochondrial NAD+ transport. Initially, subcellular
localization studies of AtNDT1 and AtNDT2 suggested that they are found in chloroplasts
and mitochondria, respectively [11]. However, later, AtNDT1 was reported to localize
to mitochondria [44], in agreement with previous unpublished results (E. Blanco and
F. Palmieri, personal communication). Both proteins are expressed in developing and
metabolically active tissues: AtNDT1 in leaf mesophyll cells and root tips; AtNDT2 in
meristematic shoots, vascular bundles of leaves, siliques, petal veins, pollen, and roots [11].
Diminished expression of AtNDT1 in Arabidopsis leads to impairments in the reproduction
system, such as reduction in pollen, silique length, and seeds, whereas the vegetative
growth is increased due to enhanced photosynthesis, leaf number, starch, and sucrose
levels [44]. Reduced expression of AtNDT2 also affects the plant reproductive phase, in this
case by decreasing seed quantity and quality [45]. Moreover, reduced AtNDT2 levels in
flowers and seedlings trigger increased expression of several enzymes involved in NAD+
biosynthesis. In conclusion, AtNDT1 and AtNDT2 catalyse the import of NAD+ into
mitochondria, probably in exchange for intramitochondrial ADP or AMP.
Two other members of the mitochondrial carrier family have been found to transport
NAD+, the human SLC25A17 and the Arabidopsis PXN. Notably, at variance to all the
other NAD+-transporting proteins mentioned above, these two carriers are localized to
peroxisomes. Both of them have been characterized biochemically by the EPRA method.
Although SLC25A17 transports NAD+ along with PAP (adenosine 3′,5′-diphosphate) and
ADP to a lesser extent than the main substrates of this carrier (CoA, FAD, FMN, and AMP),
it is most likely that SLC25A17 also plays a role in peroxisomal NAD+ import in hu-
mans [13]. PXN transports NAD+ (Km values in submillimolar range), NADH, AMP,
and ADP at low rates, in addition to CoA, dephospho-CoA, PAP, and acetyl-CoA that are
transported at higher rates [12,14], and is therefore also involved in peroxisomal NAD+
import in plants.
It should be mentioned that membrane transporters not belonging to the mitochon-
drial carrier family have also been identified to transport NAD+: the plasma membrane
nucleotide transporter NTT4 and Npt1Ct of Protochlamydia amoebophila UWE25 and Chlamy-
dia trachomatis, respectively. Both are obligate intracellular symbionts in protozoa [46,47].
These two transporters are of the NTT family, whose members are found in intracellular
bacteria and plant plastids and are predicted to have 10–12 transmembrane helices.
5. Discovery of a Mammalian Mitochondrial NAD+ Carrier
It has long been believed that in human and animal cells, there is no transport of NAD+
between mitochondria and the cytosol. This idea was supported in in vitro experiments
with mitochondria isolated from rat liver, in which it was shown that NAD+ does not
pass through the inner membrane of the organelle [36]. The absence of NAD+ transport
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between the cytosol and mitochondria was also supported by data on the maintenance
of mitochondrial NAD+ within physiological concentrations with significant depletion of
other pools (cytosolic and nuclear) evoked by genotoxic stress during treatment of cells
with the DNA alkylating agent MMS [48] or after suppression of the activity of the NAMPT
by the inhibitor FK866 [49]. The only alternative to the import of NAD+ from the cytosol
seemed to be intramitochondrial synthesis.
On the other hand, mitochondrial NAD+ carriers have been identified in yeast and
plants [10,18]. Previous attempts to detect a mitochondrial NAD+ transporter in human
cells based on homology with the characterized transporters in yeast (Ndt1p and Ndt2p)
and plants (AtNDT1 and AtNDT2) were unsuccessful. It was shown that the mitochon-
drial folate and FAD carrier SLC25A32, which is the closest homologue in mammals of
the above-mentioned characterized NAD+ transporters, does not influence mitochondrial
NAD+ [35,48]. Other potential candidates from the SLC25 family–the pyrimidine nu-
cleotide transporters SLC25A33 and SLC25A36—did not exhibit NAD+ transporter activity
either [35,50]. Consequently, alternative mechanisms of mitochondrial NAD+ generation
have been forwarded; in particular, those including mitochondrial NMNAT3 [6,35]. How-
ever, more recent research showed, albeit indirectly, that mitochondrial NAD+ originates
from the cytosol [37]. Eventually, at the end of 2020, three research groups independently
characterized the mitochondrial NAD+ transporter in human cells-SLC25A51 (also called
MCART1) [15–17].
Genetic coessentiality analyses showed strong negative interactions of SLC25A51 with
mitochondrial transporters essential for one-carbon and glutathione metabolism as well
as a strong negative interaction with the glucose transporter at the plasma membrane
SLC2A1/GLUT1. Since SLC25A51, furthermore, showed negative interactions with mito-
chondrial transporters for other cofactors, it was a likely candidate for the mitochondrial
NAD+ transporter. Targeted metabolomics in SLC25A51-deficient cells showed a deple-
tion of riboflavin as well as purine nucleotides and an increased level of glutathione
metabolism-related metabolites [15,16]. The role of SLC25A51 as a NAD+ transporter
was further confirmed through knockouts in various cell lines, which led to dramatic
impairment of mitochondrial respiration [15–17].
In a variety of cells, knockout or knockdown of the gene encoding the SLC25A51
protein resulted in a decreased oxygen consumption rate because of impaired respiratory
complex I activity [15–17]. LC-MS-based metabolomics analyses of SLC25A51 KO cells
revealed extensive alterations in major mitochondrial metabolic pathways such as the TCA
cycle, one-carbon flux, fatty acid oxidation, and ETC function [15,16]. Moreover, cells lack-
ing SLC25A51, cultivated in a medium containing galactose instead of glucose as a carbon
source, were unable to generate ATP in mitochondria [16]. Thus, SLC25A51 deficiency
led to dramatic impairment of mitochondrial respiration. Using targeted metabolomics,
a genetically encoded cpVenus NAD+ sensor or the PARAPLAY system, it was shown
that SLC25A51 deficiency selectively depleted mitochondrial (but not whole cell) NAD+,
whereas overexpression of SLC25A51 significantly increased mitochondrial NAD+ lev-
els [15–17]. It was also found that NAD+ uptake into mitochondria isolated from SLC25A51
KD or KO cells was substantially decreased compared to control mitochondria. On the
contrary, mitochondria from cells overexpressing SLC25A51 demonstrated increased NAD+
uptake capacity [16,17]. It is noteworthy that in in vitro experiments using 13C5-NAD+,
unlabelled NAD+ or NADH, but not NMN, competed for isotope-labelled NAD+ up-
take into mitochondria [16]. Moreover, to validate the function of SLC25A51 as NAD+
transporter, it was tested whether the human SLC25A51 and yeast mitochondrial NAD+
transporters Ndt1p and Ndt2p functionally substitute each other. Overexpression of the
SLC25A51 protein rescued slow growth and normalized mitochondrial NAD+ levels of the
yeast strain in which both NDT1 and NDT2 were deleted [15,16]. Ectopically expressed
SLC25A51 also fully rescued impaired uptake of 3H-NAD+ into mitochondria isolated from
NDT1 and NDT2 double knockout yeast [17]. Using this experimental system, the authors
also determined kinetic parameters of SLC25A51-mediated NAD+ transport (Km = 200 µM
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± 60 µM; Vmax = 1200 pmol sec−1 mg−1) On the other hand, overexpression of the yeast
protein Ndt1p rescued mitochondrial NAD+ levels and mitochondrial respiration in human
SLC25A51 knock out cells [15,16]. Thus, it was convincingly demonstrated that the proteins
SLC25A51 and Ndt1p (as well as Ndt2p) are functional homologues.
Despite the fact that the mitochondrial NAD+ uptake was not confirmed by a direct
transport method upon reconstitution of the protein into liposomes, it is highly probable
that SLC25A51 is indeed a mitochondrial NAD+ carrier in human cells. Further validation
and investigation will provide more insights into the transport characteristics and the
physiological effects of alterations in SLC25A51 expression.
Available data show that SLC25A51 expression is relatively constant across human
tissues, with highest expression in testis, breast, bone marrow, parathyroid gland, and adi-
pose tissues. Notably, expression of the close homologue SLC25A52 is mainly detectable in
testis with some low-level expression in other tissues [51].
6. Molecular Characterisation of the Mitochondrial Carrier SLC25A51
SLC25A51 has been included into the solute carrier family 25 (SLC25), also named mi-
tochondrial carrier family (MCF), due to the presence of three signature motif sequences in
three tandemly repeated 100-residue domains, which are characteristic for the members of
this protein family (Figure 2) [52–55]. In fact, SLC25A51 was initially called Mitochondrial
Carrier Triple Repeat Protein 1 (MCART1). Typically, each 100-residue domain of a mito-
chondrial carrier (MC) contains two transmembrane helices and the conserved residues
of the signature motif (PX[DE]XX[KR]X[KR]X20–30[DE]GXXXX[WYF][KR]G; PROSITE
PS50920, PFAM PF00153, and IPR00193). The first part of the signature motif
(PX[DE]XX[KR]X[KR) marks the end of the odd-numbered transmembrane helices, whereas
the last residues are located just before the beginning of the even-numbered transmem-
brane helices. In humans, the SLC25 family consists of 53 members annotated from
SLC25A1 to SLC25A53 and many of them have been found to transport nucleotides,
amino acids, carboxylates, inorganic anions, and cofactors across the inner mitochondrial
membrane [18,56–58], and mutations in 18 of these MCs cause human diseases [59]. The six
transmembrane helices (H1–H6) of MCs are structured in a barrel around a central substrate
translocation pore [60–62] and the N- and C-termini of the proteins are in the mitochondrial
intermembrane space [63–65].
SLC25A51 is quite different from the other members of the SLC25 family, displaying
distinct variations as shown by sequence comparison with typical SLC25 representatives
(see Figure 2). Most noteworthy, the signature motif lacks the first negatively charged
residue in the first and third repeat (exhibiting a glutamine and an asparagine, respectively),
the first positively charged residue in the first and second repeats (showing a leucine and
a glutamine, respectively), as well as the first glycine in the third repeat (having a lysine)
(Figure 2). In the conformational changes of MCs occurring during the translocation of the
substrates, the first two charged residues of each signature motif form an interconnected
charged network of salt bridges between H1, H3, and H5 that take part in the closing of the
substrate translocation pore towards the mitochondrial matrix (i.e., of the matrix gate) [60].
Given that SLC25A51 lacks many of the aforementioned charged residues in the signature
motif, it is left with only one salt bridge (between H3 and H5) out of the three characteristic
ones of the matrix gate. Other differences of SLC25A51 with respect to the sequence features
of a typical MC are: the possibility of only one salt bridge (between H4 and H6) out of the
usual three of the cytoplasmic gate (which closes the substrate translocation pore towards
the intermembrane space) and the lack of cardiolipin-binding motif 1 (Figure 2) [62].
By contrast, other MC motifs are quite conserved in SLC25A51: the GXXXG motif and other
small residues taking part in helical packing, the cardiolipin-binding motif 2 (corresponding
to the last three residues of the signature motif), and the glutamine and tyrosine braces
participating in the matrix and cytoplasmic gates, respectively (Figure 2) [66].
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Figure 2. Sequence comparison of the three mitochondrial carrier domain repeats in nucleotide transporter SLC25A4
(ADP/ATP carrier 1, AAC1), carboxylate transporter SLC25A1 (citrate carrier, CIC), phosphate transporter SLC25A3
(PiC), proton transporter SLC25A7 (uncoupling protein 1, UCP1), amino acid transporter SLC25A12 (aspartate-glutamate
carrier 1, AGC1), NAD+ transporter Ndt1p (S. cerevisiae), SLC25A51, and SLC25A52. The following sequence features
are indicated: position of the transmembrane helices H1-6 (a line above the sequences), the conserved residues (bold),
the helical packing GXXXG motif (cyan), other helical packing small amino acids (light grey), the signature motif sequences
(green), the glutamine and tyrosine braces (dark grey), the cardiolipin-binding motif 1 (olive), the contact point residues of
the proposed substrate binding site (yellow), and the negatively (red) and positively (blue) charged residues of the cytosolic
gate. The distinct sequence variations in SLC25A51 (and SLC25A52) discussed in the text are indicated in magenta.
Based on available structures of the ADP/ATP carrier [60,61], which have been used
to understand substrate binding and the translocation mechanism of MCs, a 3D-model of
SLC25A51 was generated in a conformation with the matrix gate closed and the cytoplasmic
gate open (Figure 3). The substrate binding site of MCs is mainly formed by the so-
called “contact point” residues (indicated in yellow in Figure 2), which are located in the
even-numbered transmembrane helices and protrude in the substrate translocation pore
approximately at the midpoint of the membrane between the matrix and cytoplasmic gates
(four, two, and one residues on H2, H4, and H6, respectively, Figure 3) [67]. NAD+ was
docked into the SLC25A51 homology model to get structural insight into protein-substrate
interactions (Figure 3). In the highest-rated docking solution, NAD+ is bound in the central
cavity of the SLC25A51 structural model at the midpoint between the intermembrane
space and the matrix sides of the membrane, and between the cytoplasmic and matrix
gate areas (Figure 3A). It is noteworthy that the substrate interacts with residues of all
six transmembrane helices (Figure 3B) and forms a total of nine hydrogen bonds with
the carrier. In particular, NAD+ is bound through hydrogen bonds with each of the three
contact points interacting with six out of the seven contact point residues. Of course,
the hypothetical substrate binding site of SLC25A51, suggested by this docking solution,
awaits experimental validation. However, it is worth mentioning that in most of the
other lower-ranking docking solutions, NAD+, although having different conformations
and interacting with different residues, was bound at the midpoint of the membrane
through multiple hydrogen bonds with contact point residues and other residues of all the
transmembrane helices. Most likely, this is a consequence of NAD+ being one of the largest
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substrates known for mitochondrial carriers and having many potential hydrogen bond
donors and acceptors.
Figure 3. Docking of NAD+ into the structural homology model of SLC25A51. A structural homology
model of SLC25A51 was generated based on the bovine and yeast ADP/ATP carrier structures (PDB
ID: 1OKC, 4C9Q, and 4C9G) by Modeller [68]. Conformationally flexible NAD+ was docked into
the active site of the SLC25A51 structural model with flexible side chains by Autodock Vina [69].
(A) The highest-ranked docking solution (binding energy = −9.9 kcal/mol; interface area = 532 Å2)
is displayed with the protein in cartoon with rainbow colours from N-terminus (blue) to C-terminus
(red) and NAD+ in spheres (carbons in magenta) viewed from the mitochondrial inner membrane
plane. (B) The residues of the substrate binding site of the same docking solution are viewed from
the intermembrane space side: NAD+ and the residues interacting with it are shown in ball-and-stick
and sticks, respectively, with carbons in the same colour as in (A).
7. Hypotheses about the Evolution of SLC25A51
The SLC25A51 gene is conserved with at least 45% sequence identity on protein level
in mammals, birds, fish, amphibians, insects, and nematodes (Figure 4). Notably, it is not
found in plants or fungi, where other MCs have been found to transport NAD+ [10–14].
Human SLC25A51 is a close paralog of SLC25A52 (Figure 2, sharing 96% identical amino
acid sequence, also called MCART2) and, to a lesser extent, to SLC25A53 (30% sequence
identity, MCART6) [15–17]. These three MCs are found on the same branch in phylogenetic
trees and are distinct from all other human SLC25 members [18,70,71]. They are also
distant from all other MCs known to transport NAD+ (less than 18% overall sequence iden-
tity): the human peroxisomal SLC25A17 [13]; yeast mitochondrial Ndt1p and Ndt2p [10];
Arabidopsis thaliana AtNDT1 and AtNDT2 [11] and peroxisomal PXN [12,14]. Differently
from these NAD+-transporting carriers, SLC25A51, SLC25A52, and SLC25A53 do not have
a tryptophan, instead of the first negatively charged residue in the second signature motif
(Figure 2). SLC25A33 and SLC25A36 have this tryptophan too, although they transport
pyrimidine nucleotides and not NAD+ [50]. Furthermore, the residues of the contact points
and the conserved three-fold-symmetry-related positions typical for NAD+-transporting
MCs are different from those of SLC25A51, which are almost identical to those of SLC25A52
and SLC25A53. Moreover, it is noteworthy that the genes of human SLC25A51, SLC25A52,
and SLC25A53 do not have introns, although homologues in lower species do. SLC25A51
first appeared in Protostomia and is related to oxaloacetate-type SLC25 transporters [72].
SLC25A53 appears to have evolved from SLC25A51 in vertebrates, whereas SLC25A52 can
only be found in primates (schematic overview Figure 5). Plant and fungal Ndt1/2, on the
other hand, appear to have evolved independently and are more closely related to the
mitochondrial folate and FAD transporters [73,74]. In addition, our analyses indicate that
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SLC25A51 binds NAD+ in a different way than the yeast and plant MCs transporting NAD+
given that their sequences and the residues of their substrate binding sites are so different.
Figure 4. Multiple sequence alignment of representative SLC25A51 homologs from various species: human (Homo sapiens,
NP_219480), bovine (Bos taurus, NP_001092864), mouse (Mus musculus, NP_001009949), bird (Gallus gallus, XP_003643156),
fish (Danio rerio, XP_002664343), insect (Drosophila melanogaster, NP_651766), nematode (Caenorhabditis elegans, NP_501642),
and frog (Xenopus tropicalis, NP_001107506). The conserved residues are coloured based on the property of the side chain:
hydroxyl group S and T (magenta); amide group N and Q (green); positively charged R, K, and H (cyan); negatively charged
D and E (red); aromatic F, W, and Y (brown); sulfur-containing C and M (light yellow); hydrophobic A, G, L, I, and V (black
and bold); P (dark yellow).
Figure 5. Evolutionary events related to compartmentation of NAD+ biosynthesis. The scheme
illustrates major evolutionary events related to mitochondrial NAD+ metabolism. Ndt1/2 can only
be found in plants and fungi, whereas SLC25A51 homologues can be detected in all Metazoan
starting from Protostomia. The functionally uncharacterized paralogue SLC25A53 is first found in
vertebrates, whereas SLC25A52 can only be found in primates. In parallel, the different isoforms of
NMNATs developed. The first duplication of NMNATs in the last common ancestor of vertebrates
gave rise to NMNAT2, whereas the later gene duplication in mammals lead to the development of
the mitochondrial isoform NMNAT3 [75]. The tree is a schematic representation of selected taxa and
is based on information from Tree of Life Web Project [76].
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8. Conclusions and Perspectives
The identification of SLC25A51 as a human mitochondrial NAD+ carrier is a leap
forward in understanding cellular NAD+ metabolism and how NAD+ pools are distributed
between the cytoplasm and mitochondria. It strengthens the hypothesis that NAD+ biosyn-
thesis does not necessarily occur in mitochondria. Just as its counterparts in yeast and
plants, as well as the peroxisomal NAD+ carriers, the mitochondrial NAD+ transporter of
animals—SLC25A51—is a member of the mitochondrial carrier SLC25 family. However,
it seems to have a distant evolutionary origin and a different substrate binding site with
respect to the other NAD+ carriers. The appearance of SLC25A51 in Protostomia may
reflect changes or differences in cellular NAD+ utilization, metabolism, and regulation
compared to lower organisms or to yeast and plants.
On the other hand, the discovery of a human mitochondrial NAD+ carrier SLC25A51
raises a number of important questions, which need to be addressed in future research.
What is the role of NMNAT3 in mitochondria? Is NMNAT3 involved in regulation of the
mitochondrial NAD+ pool, in the synthesis or degradation of NAD+ from or to NMN in
certain cells or conditions? Does SLC25A51 play a role in the concentration gradient of
NAD+ between mitochondria and cytoplasm (higher in mitochondria) of various tissues
and cell types? The transport properties of SLC25A51 have not been defined yet. What is
the substrate specificity of SLC25A51? What is its ability to transport putative substrates
such as NAD+, NMN, NAAD, α-NAD+, NADH, NAMN, NADP, NADPH, Nam, NA, FAD,
FMN, and (deoxy-) nucleotides? Does SLC25A51 catalyse unidirectional transport and/or
antiport of substrates, and what are its kinetic parameters? A biochemical characterization
of SLC25A51 to answer the last two questions would help to understand what the phys-
iological substrates of this carrier protein are and the preferred direction. An additional
area of interest for future studies is in elucidating how this transporter is regulated in vivo,
for example, by post-translational modifications. Regulation could be critical, because high
expression of the carrier or a functional homolog affects mitochondrial function. A further
issue is that SLC25A51 does not appear to be essential, suggesting that there may be other
mitochondrial transporters capable of transporting NAD. The very close paralog SLC25A52
is likely to have similar transport properties as SLC25A51, but there could be differences.
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